3 recruiting, 2 terminated, 1 withdrawn. 4 Phase 2, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Not applicable | 1 | Recruiting 1 |
Follow PR-Positive Breast Cancer: new trials by email Literature Review of PR-Positive Breast Cancer trials Research Report on PR-Positive Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Supporting Health Including Endocrine Treatment for Long Duration SHIELD portal - Breast Cancer, Breast Cancer - Female | Not applicable | Recruiting | Dana-Farber Cancer Institute | 30 | 2026-08-04 | 2026-08-10 |
| Fulvestrant + Neratinib In Breast Cancer NERATINIB, FULVESTRANT - Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer | Phase 2 | Withdrawn | Massachusetts General Hospital | 2023-07-01 | 2023-08-01 | |
| PRE-ISPY Phase I/II Oncology Platform Program ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab - HER2-positive Breast Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 280 | 2023-02-15 | 2026-09-30 |
| Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers Neratinib, Letrozole (L) or Anastrozole (A), Trastuzumab - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Recruiting | Ruth O'Regan | 30 | 2022-07-21 | 2026-09-03 |
| Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer Infigratinib, Tamoxifen, Omnipaque 350 - Breast Cancer, HER2-negative Breast Cancer | Phase 1 | Terminated | Jennifer Lee Caswell-Jin | 4 | 2020-10-13 | 2026-02-12 |
| A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) Zilovertamab vedotin - Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer | Phase 2 | Terminated | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 102 | 2020-10-07 | 2025-11-10 |
Breast Neoplasms (5) · Neoplasm Metastasis (2) · Triple Negative Breast Neoplasms (2) · Adenocarcinoma (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Neoplasm, Residual (1) · Pancreatic Neoplasms (1) · Rectal Neoplasms (1) · Stomach Neoplasms (1)
Breast Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Breast Neoplasms (1) · Carcinoma (1) · Colonic Diseases (1)
neratinib (2) · ALX148 (1) · Anastrozole (1) · Fulvestrant (1) · Iohexol (1) · Iopamidol (1) · Letrozole (1) · Tamoxifen (1) · Tomography, X-Ray Computed (1) · Trastuzumab (1) · infigratinib (1) · tucatinib (1) · zanidatamab (1)
Dana-Farber Cancer Institute (1) · Jennifer Lee Caswell-Jin (1) · Massachusetts General Hospital (1) · QuantumLeap Healthcare Collaborative (1) · Ruth O'Regan (1) · VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)
United States (6) · Canada (1)
Aditya Bardia, MD,MPH (1) · Ann H Partridge, MD, MPH (1) · Jennifer Lee Caswell-Jin (1) · Paula R Pohlmann, MD, MSc, PhD (1) · Ruth O'Regan, MD (1)
K08CA252457 (1)